Obesity and cancer research has built a substantial evidence base over the past decade, but a new analysis from the National Cancer Institute says important scientific gaps remain. In a Special Communication published in JAMA Network Open, researchers reviewed federal grant data from fiscal years 2015 through 2022 to examine how consistently obesity and cancer research has been supported. Their assessment indicates sustained investment in the field, reflecting the growing recognition that excess adiposity is not simply a risk factor for a limited number of tumors, but a complex biological and social condition that may influence cancer development, progression, treatment, and long-term outcomes.
The analysis comes as scientists increasingly understand obesity as a state of chronic metabolic and inflammatory disruption. Adipose tissue is an active endocrine organ that releases hormones, cytokines, growth factors, and other signaling molecules. In obesity, changes in these biological systems can promote insulin resistance, altered estrogen and androgen signaling, persistent low-grade inflammation, oxidative stress, and changes in immune-cell function. These processes may affect the initiation of malignant disease as well as the behavior of established tumors. Obesity has been associated with increased risk for several cancer types, although the strength and mechanisms of those associations vary according to tumor site, sex, age, body-fat distribution, metabolic health, and other factors.
By examining grant activity rather than focusing on a single disease or intervention, the NCI authors sought to characterize the overall direction of the research enterprise. Grant portfolios can reveal which questions attract sustained scientific attention and which areas may remain comparatively underdeveloped. The authors’ review supports continued investment in obesity and cancer research, particularly because the existing evidence has not fully resolved how body weight, adipose biology, metabolic dysfunction, and cancer outcomes interact. The findings also point to opportunities for a more balanced research agenda that moves beyond the question of whether obesity is associated with cancer and toward determining when, why, and for whom those associations matter.
One priority identified by the authors is the relationship between obesity and cancer treatment. Obesity can alter drug distribution, metabolism, and clearance, potentially affecting the pharmacokinetics of chemotherapy, targeted therapies, immunotherapies, and hormonal treatments. Body composition may be more informative than body mass index alone in some clinical settings, because two patients with the same BMI can have markedly different proportions of muscle, visceral fat, and subcutaneous fat. Excess adiposity may also influence surgical risk, radiation planning, treatment-related toxicity, immune responses, and the ability to maintain treatment intensity. More research is needed to determine how these mechanisms should shape dosing, clinical-trial design, supportive care, and personalized treatment decisions.
Survivorship represents another area in which the evidence remains incomplete. As the number of people living after a cancer diagnosis grows, researchers are examining how obesity affects recurrence, second primary cancers, cardiovascular disease, functional decline, and quality of life. Weight change after diagnosis may have different meanings depending on whether it is intentional, treatment-related, or caused by illness. Survivors may also face limitations in physical activity, persistent fatigue, endocrine changes, and treatment-induced metabolic disturbances that complicate weight-management efforts. Longitudinal studies that follow patients from diagnosis through extended survivorship could help distinguish associations from causal pathways and identify interventions that improve both cancer-related and overall health outcomes.
The NCI communication also highlights the need to study obesity and cancer across the lifespan. Biological exposure to excess adiposity may have different consequences during childhood, adolescence, reproductive years, and older age. Early-life obesity can influence puberty, hormonal development, immune regulation, and the duration of exposure to metabolic abnormalities. In older adults, meanwhile, intentional weight loss must be considered alongside frailty, sarcopenia, nutritional adequacy, and competing health risks. Research spanning multiple stages of life could clarify how the timing, duration, and severity of obesity contribute to cancer risk and whether prevention strategies have different effects at different ages.
Cancer disparities are another major research opportunity. Obesity prevalence, access to preventive care, cancer screening, treatment quality, environmental exposures, and opportunities for healthy physical activity are not distributed equally across populations. Race and ethnicity, income, geography, disability, education, food access, and experiences of discrimination can intersect to shape both obesity and cancer outcomes. The authors call for research capable of separating biological mechanisms from the effects of social and structural conditions. Such work could help prevent the misuse of body weight as an individual-level explanation for unequal outcomes and instead support interventions that address the environments and systems in which health risks develop.
The report further encourages broader study across multiple cancer sites. Research has often concentrated on a subset of malignancies with well-established obesity associations, while other tumor types and less common cancers have received less attention. A multi-site approach could reveal shared mechanisms, such as insulin and insulin-like growth factor signaling, chronic inflammation, altered sex-hormone activity, and immune dysregulation, while also identifying cancer-specific pathways. The authors note that the expanding use of glucagon-like peptide-1, or GLP-1, medications creates an additional frontier. These drugs can produce substantial pharmacologically induced weight loss and may improve glucose regulation and other metabolic measures, but their long-term effects on cancer risk, treatment response, recurrence, and survivorship remain important unanswered questions.
The emergence of GLP-1 medications does not by itself establish that intentional weight loss prevents cancer or improves outcomes, and the researchers emphasize the need for rigorous investigation rather than premature conclusions. Future studies could compare different causes of weight loss, including lifestyle interventions, metabolic surgery, and pharmacologic treatment, while measuring changes in body composition, inflammatory markers, insulin sensitivity, tumor biology, and patient-centered outcomes. Randomized trials, prospective cohorts, linked clinical and genomic datasets, and carefully designed survivorship studies may help determine whether reducing adiposity changes cancer biology directly or whether benefits arise primarily through improved metabolic health. The NCI analysis ultimately presents obesity and cancer as a multidisciplinary research challenge—one requiring coordination among epidemiology, molecular biology, oncology, pharmacology, health services research, and population health to guide prevention and treatment in an era of rapidly changing weight-management therapies.
Subject of Research: Obesity and cancer research funding, treatment, survivorship, disparities, lifespan, multiple cancer sites, and GLP-1-associated weight loss.
Web References: https://doi.org/10.1001/jamanetworkopen.2026.28773
References: Special Communication from the National Cancer Institute published in JAMA Network Open, DOI: 10.1001/jamanetworkopen.2026.28773.
Keywords: Obesity; cancer research; oncology; cancer treatment; cancer survivorship; weight loss; GLP-1 medications; pharmacology; cancer risk; disparities; lifespan; data analysis.
